Corcept Therapeutics (CORT) to Release Quarterly Earnings on Wednesday

Corcept Therapeutics (NASDAQ:CORT) is anticipated to announce its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect the company to announce earnings of $0.0123 per share and revenue of $219.1260 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 5:00 PM ET.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.19). The company had revenue of $164.90 million for the quarter, compared to analyst estimates of $185.83 million. Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period last year, the business earned $0.17 EPS. On average, analysts expect Corcept Therapeutics to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Corcept Therapeutics Stock Down 4.4%

NASDAQ:CORT opened at $91.12 on Tuesday. Corcept Therapeutics has a twelve month low of $28.66 and a twelve month high of $97.63. The company has a fifty day moving average of $81.12 and a 200-day moving average of $55.00. The firm has a market capitalization of $9.78 billion, a P/E ratio of 260.35 and a beta of 0.47.

Insider Activity

In related news, Director David L. Mahoney sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $84.53, for a total transaction of $1,690,600.00. Following the transaction, the director directly owned 26,147 shares of the company’s stock, valued at $2,210,205.91. This trade represents a 43.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Sean Maduck sold 25,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $88.35, for a total transaction of $2,208,750.00. Following the completion of the transaction, the insider directly owned 9,755 shares in the company, valued at $861,854.25. This trade represents a 71.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 300,000 shares of company stock worth $22,088,050. Company insiders own 20.70% of the company’s stock.

Institutional Investors Weigh In On Corcept Therapeutics

Several institutional investors have recently made changes to their positions in CORT. State Street Corp lifted its holdings in shares of Corcept Therapeutics by 0.5% during the 4th quarter. State Street Corp now owns 2,986,056 shares of the biotechnology company’s stock worth $103,915,000 after acquiring an additional 15,656 shares during the last quarter. Morgan Stanley raised its holdings in Corcept Therapeutics by 34.1% in the 4th quarter. Morgan Stanley now owns 1,592,059 shares of the biotechnology company’s stock worth $55,404,000 after purchasing an additional 405,081 shares in the last quarter. AQR Capital Management LLC raised its stake in Corcept Therapeutics by 546.9% in the third quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock worth $125,264,000 after buying an additional 1,274,215 shares in the last quarter. Epoch Investment Partners Inc. raised its position in shares of Corcept Therapeutics by 10.7% in the 3rd quarter. Epoch Investment Partners Inc. now owns 847,104 shares of the biotechnology company’s stock worth $70,403,000 after acquiring an additional 81,700 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in Corcept Therapeutics by 11.5% in the fourth quarter. Invesco Ltd. now owns 816,996 shares of the biotechnology company’s stock worth $28,431,000 after purchasing an additional 84,413 shares in the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Piper Sandler increased their price objective on shares of Corcept Therapeutics from $73.00 to $88.00 and gave the stock an “overweight” rating in a research report on Friday, May 1st. Weiss Ratings reiterated a “hold (c-)” rating on shares of Corcept Therapeutics in a report on Wednesday, June 24th. Zacks Research raised Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 4th. UBS Group set a $135.00 target price on Corcept Therapeutics in a research report on Thursday, May 28th. Finally, Wolfe Research reissued an “underperform” rating and issued a $50.00 price target on shares of Corcept Therapeutics in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Corcept Therapeutics has an average rating of “Moderate Buy” and an average target price of $92.17.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.